Indigo BioAutomation Joins the Tetra Partner Network to Bring Highly Automated Data Analysis to Pharmaceutical Customers

Partnership Showcases the Power of Tetra Data to Amplify Scientific and Regulatory Outcomes

TetraScience, the R&D Data Cloud company, announced that Indigo BioAutomation, the leader in automated data analysis for the clinical testing industry, has joined the Tetra Partner Network to help pharmaceutical customers vastly improve the efficiency and effectiveness of their pharmaceutical development and manufacturing.

“We are thrilled to partner with Indigo BioAutomation, who are renowned for their proven and compliant data automation capabilities,” said Simon Meffan-Main, Ph.D, Vice President of Product, Tetra Partner Network.  “Indigo are acknowledged regulatory experts with deep expertise across a wide range of laboratory applications and technologies. By combining our strengths, we can help scientists rapidly uncover insights and regulatory issues; Indigo’s recent response to Covid PCR testing illustrates the enormous adaptability of their technology to solve problems across a multitude of testing modalities.”

Download Our Top Whitepaper : Building Reliable and Secure Fintech Systems in 2022

The Tetra R&D Data cloud produces Tetra Data, which engineers previously incompatible data formats into a universally adoptable, accessible format that is comprehensive, containing raw data, processed results, and context. Indigo’s flagship products ASCENT and ARQ analyze more than 2 billion individual measurements a year and currently accelerate the release of over 3 million production and R&D samples a month from multiple incoming data sources. By combining Tetra Data with Indigo, laboratory results can be visualized at scale with automated assessment, review, and dispositioning of quality issues as part of a release workflow even in the tightly regulated biopharma industry.

“We are excited to partner with TetraScience because the Tetra R&D Data Cloud makes it possible to bring Indigo’s analytical capabilities to bear on critical decisions about pharmaceutical compounds and studies,” said Randall Julian, Ph.D., CEO and Founder of Indigo BioAutomation. “By combining large-scale analytics and integrative support with the fidelity of Tetra Data, pharmaceutical companies can make better, more reliable decisions through more effective collaboration across all parts of their organization, including external partners, helping regulators speed much-needed new therapeutics to market.”

“Industry participants of all kinds – global pharmas, biotech startups, informatics providers, CROs, biopharma app companies, and more – recognize that this movement to the R&D Data Cloud must be driven by vendor-neutral and open partnerships that are deeply data-centric,” said Patrick Grady, CEO of TetraScience. “Biopharma R&D needs to unify and harmonize experimental data in the cloud, in order to fully capitalize on the power of AI and data science. In turn, AI and data science will uncover insights that will accelerate discovery and development of therapeutics that extend and enhance human life. We are thrilled to further extend this network together with Indigo BioAutomation.”

Recommended AI News: AudioEye Acquires The Bureau of Internet Accessibility

[To share your insights with us, please write to sghosh@martechseries.com]